Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 18/20 | 0.88 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.67 |
| ▸ | HCK | P08631 | 3/20 | 0.65 |
| ▸ | SRC | P12931 | 3/20 | 0.65 |
| ▸ | MAPK12 | P53778 | 3/20 | 0.65 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28707062 | 1.00 | BRAF (0.88) | BRAFKCNH2HCKSRCMAPK12 | |
| SCHEMBL29618923 | 0.94 | BRAF (1.00) | BRAFKCNH2HCKSRCMAPK12 | |
| SCHEMBL3763358 | 0.94 | BRAF (1.00) | BRAFKCNH2HCKSRCMAPK12 | |
| SCHEMBL3164633 | 0.92 | BRAF (0.83) | BRAFKCNH2HCKSRCMAPK12 | |
| SCHEMBL28700803 | 0.92 | BRAF (0.88) | BRAFKCNH2HCKSRCMAPK12 | |
| SCHEMBL28698521 | 0.92 | BRAF (0.91) | BRAFKCNH2HCKSRCMAPK12 | |
| SCHEMBL28685990 | 0.91 | BRAF (0.89) | BRAFKCNH2HCKSRCMAPK12 | |
| SCHEMBL3173602 | 0.91 | BRAF (1.00) | BRAFKCNH2HCKSRCMAPK12 | |
| SCHEMBL31046800 | 0.91 | BRAF (1.00) | BRAFKCNH2HCKSRCMAPK12 | |
| SCHEMBL29437796 | 0.91 | BRAF (1.00) | BRAFKCNH2HCKSRCMAPK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230089368-A1 | POLYAROMATIC UREA DERIVATIVES AND THEIR USE IN THE TREATMENT OF MUSCLE DISEASES | ANAGENESIS BIOTECHNOLOGIES S.A.S. (FR) | 2023-03-23 | — | — | US | claimed |
| US-20230089368-A1 | POLYAROMATIC UREA DERIVATIVES AND THEIR USE IN THE TREATMENT OF MUSCLE DISEASES | ANAGENESIS BIOTECHNOLOGIES S.A.S. (FR) | 2023-03-23 | — | — | US | disclosed |
| EP-3999057-A1 | POLYAROMATIC UREA DERIVATIVES AND THEIR USE IN THE TREATMENT OF MUSCLE DISEASES | ANAGENESIS BIOTECHNOLOGIES SAS (FR) | 2022-05-25 | — | — | EP | disclosed |
| CN-114144410-A | Polyarylurea derivatives and their use in the treatment of muscular diseases | 阿纳格纳斯生物技术股份有限公司 | 2022-03-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230089368-A1 | POLYAROMATIC UREA DERIVATIVES AND THEIR USE IN THE TREATMENT OF MUSCLE DISEASES | CKMT1A; CKMT1B, TNNC1, UBQLN2 | BRAF 4620/4885KCNH2 4463/4885HCK 4778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.